Editorial commentary: Asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials

doi:10.1093/cid/cis274

Comment

. 2012 Jun;54(12):1710-3.

doi: 10.1093/cid/cis274. Epub 2012 Mar 30.

Editorial commentary: Asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials

John H Powers¹

Affiliations

Affiliation

¹ Scientific Applications International Corporation, in support of the Collaborative Clinical Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. powersjohn@mail.nih.gov

PMID: 22467671
PMCID: PMC3404714
DOI: 10.1093/cid/cis274

Comment

Editorial commentary: Asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials

John H Powers. Clin Infect Dis. 2012 Jun.

. 2012 Jun;54(12):1710-3.

doi: 10.1093/cid/cis274. Epub 2012 Mar 30.

Author

John H Powers¹

Affiliation

¹ Scientific Applications International Corporation, in support of the Collaborative Clinical Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. powersjohn@mail.nih.gov

PMID: 22467671
PMCID: PMC3404714
DOI: 10.1093/cid/cis274

No abstract available

PubMed Disclaimer

Comment on

Excess deaths associated with tigecycline after approval based on noninferiority trials.
Prasad P, Sun J, Danner RL, Natanson C. Prasad P, et al. Clin Infect Dis. 2012 Jun;54(12):1699-709. doi: 10.1093/cid/cis270. Epub 2012 Mar 30. Clin Infect Dis. 2012. PMID: 22467668 Free PMC article.

Cited by

The Development of Third-Generation Tetracycline Antibiotics and New Perspectives.
Rusu A, Buta EL. Rusu A, et al. Pharmaceutics. 2021 Dec 5;13(12):2085. doi: 10.3390/pharmaceutics13122085. Pharmaceutics. 2021. PMID: 34959366 Free PMC article. Review.
The evolution of the regulatory framework for antibacterial agents.
Rex JH, Goldberger M, Eisenstein BI, Harney C. Rex JH, et al. Ann N Y Acad Sci. 2014 Sep;1323(1):11-21. doi: 10.1111/nyas.12441. Epub 2014 May 2. Ann N Y Acad Sci. 2014. PMID: 24797794 Free PMC article. Review.
Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections.
Lee YT, Tsao SM, Hsueh PR. Lee YT, et al. Eur J Clin Microbiol Infect Dis. 2013 Sep;32(9):1211-20. doi: 10.1007/s10096-013-1870-4. Epub 2013 Apr 5. Eur J Clin Microbiol Infect Dis. 2013. PMID: 23553594

References

1. Prasad P, Sun J, Danner R, Natanson C. Excess deaths associated with tigecycline after approval based on non-inferiority trials. 2012;54:1699–709. - PMC - PubMed
1. US Food and Drug Administration. FDA Drug Safety Communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. US Food and Drug Administration. 1 September 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm . Accessed 19 April 2012.
1. Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2011;55:1162–72. - PMC - PubMed
1. Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11:834–44. - PubMed
1. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66:1963–71. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Prasad P, Sun J, Danner R, Natanson C. Excess deaths associated with tigecycline after approval based on non-inferiority trials. 2012;54:1699–709. - PMC - PubMed

[2] Prasad P, Sun J, Danner R, Natanson C. Excess deaths associated with tigecycline after approval based on non-inferiority trials. 2012;54:1699–709. - PMC - PubMed

[3] US Food and Drug Administration. FDA Drug Safety Communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. US Food and Drug Administration. 1 September 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm . Accessed 19 April 2012.

[4] US Food and Drug Administration. FDA Drug Safety Communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. US Food and Drug Administration. 1 September 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm . Accessed 19 April 2012.

[5] Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2011;55:1162–72. - PMC - PubMed

[6] Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2011;55:1162–72. - PMC - PubMed

[7] Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11:834–44. - PubMed

[8] Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11:834–44. - PubMed

[9] Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66:1963–71. - PubMed

[10] Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66:1963–71. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Editorial commentary: Asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials

Affiliation

Editorial commentary: Asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials

Author

Affiliation

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical